FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 556 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Patritumab Deruxtecan Demonstrates a Manageable Safety Profile and Durable Efficacy in... October 19, 2023 News digest – targeted ‘lava lamp’ treatment, skin cancer biopsies and... June 20, 2020 Pyrotinib in HER2-mutated Advanced NSCLC Previously Treated with Chemotherapy July 13, 2020 FDA Says Breast Implant Cancer Risk Is Not Enough to Warrant... May 3, 2019 Load more HOT NEWS Nivolumab Achieves High ORR and Durable PFS in Patients with dMMR/MSI-H... Cancer Control in American Indian and Alaska Native Populations: A Conversation... Withdrawal of Application to Change the EU Marketing Authorisation for Cervarix ΚΑΡΚΙΝΟΣ ΤΡΑΧΗΛΟΥ ΜΗΤΡΑΣ
